Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA T-Cell therapy Market, by End User
1.4.2 LAMEA T-Cell therapy Market, by Indication
1.4.3 LAMEA T-Cell therapy Market, by Therapy Type
1.4.4 LAMEA T-Cell therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
Chapter 4. LAMEA T-Cell therapy Market by End User
4.1 LAMEA Hospitals Market by Country
4.2 LAMEA Cancer Treatment Centers Market by Country
Chapter 5. LAMEA T-Cell therapy Market by Indication
5.1 LAMEA Lymphoma Market by Country
5.2 LAMEA Acute Lymphocytic Leukemia Market by Country
5.3 LAMEA Others Market by Country
Chapter 6. LAMEA T-Cell therapy Market by Therapy Type
6.1 LAMEA CAR T-Cell Therapy Market by Country
6.2 LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type
6.2.1 LAMEA Axicabtagene Ciloleucel Market by Country
6.2.2 LAMEA Tisagenlecleucel Market by Country
6.2.3 LAMEA Brexucabtagene Autoleucel Market by Country
6.2.4 LAMEA Others Market by Country
6.3 LAMEA T-Cell Receptor (TCR)-Based Market by Country
Chapter 7. LAMEA T-Cell therapy Market by Country
7.1 Brazil T-Cell therapy Market
7.1.1 Brazil T-Cell therapy Market by End User
7.1.2 Brazil T-Cell therapy Market by Indication
7.1.3 Brazil T-Cell therapy Market by Therapy Type
7.1.3.1 Brazil T-Cell therapy Market by CAR T-Cell Therapy Type
7.2 Argentina T-Cell therapy Market
7.2.1 Argentina T-Cell therapy Market by End User
7.2.2 Argentina T-Cell therapy Market by Indication
7.2.3 Argentina T-Cell therapy Market by Therapy Type
7.2.3.1 Argentina T-Cell therapy Market by CAR T-Cell Therapy Type
7.3 UAE T-Cell therapy Market
7.3.1 UAE T-Cell therapy Market by End User
7.3.2 UAE T-Cell therapy Market by Indication
7.3.3 UAE T-Cell therapy Market by Therapy Type
7.3.3.1 UAE T-Cell therapy Market by CAR T-Cell Therapy Type
7.4 Saudi Arabia T-Cell therapy Market
7.4.1 Saudi Arabia T-Cell therapy Market by End User
7.4.2 Saudi Arabia T-Cell therapy Market by Indication
7.4.3 Saudi Arabia T-Cell therapy Market by Therapy Type
7.4.3.1 Saudi Arabia T-Cell therapy Market by CAR T-Cell Therapy Type
7.5 South Africa T-Cell therapy Market
7.5.1 South Africa T-Cell therapy Market by End User
7.5.2 South Africa T-Cell therapy Market by Indication
7.5.3 South Africa T-Cell therapy Market by Therapy Type
7.5.3.1 South Africa T-Cell therapy Market by CAR T-Cell Therapy Type
7.6 Nigeria T-Cell therapy Market
7.6.1 Nigeria T-Cell therapy Market by End User
7.6.2 Nigeria T-Cell therapy Market by Indication
7.6.3 Nigeria T-Cell therapy Market by Therapy Type
7.6.3.1 Nigeria T-Cell therapy Market by CAR T-Cell Therapy Type
7.7 Rest of LAMEA T-Cell therapy Market
7.7.1 Rest of LAMEA T-Cell therapy Market by End User
7.7.2 Rest of LAMEA T-Cell therapy Market by Indication
7.7.3 Rest of LAMEA T-Cell therapy Market by Therapy Type
7.7.3.1 Rest of LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type
Chapter 8. Company Profiles
8.1 Merck KGaA
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Johnson & Johnson
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Gilead Sciences, Inc.
8.4.1 Company overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Acquisition and Mergers:
8.4.4.3 Trials and Approvals:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.6.5.3 Trials and Approvals:
8.7 Sorrento Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Trials and Approvals:
8.8 Bristol Myers Squibb Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.5.3 Geographical Expansions:
8.8.5.4 Trials and Approvals:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.10. Immunocore Holdings plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Trials and Approvals:
Unique Offerings 
